Pharmaceutical Executive Daily: Peptide Ruling Stalls
Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharmaceutical Executive
Pharmaceutical Executive Daily: FDA Approves Tukysa Plus Trastuzumab and Pertuzumab
Pharmaceutical Executive Daily: What HCP Engagement Actually Looks Like
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
Pharmaceutical Executive Daily: CSL & Alentis Enter $1.6 Billion Global Partnership
Get summaries like this every morning.
Free AI-powered recaps of Pharmaceutical Executive and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.